Boston Scientific's Fourth-Generation Vercise Genus Deep Brain Stimulation System Receives FDA Approval for Adjunctive Treatment of Parkinson’s Disease

On January 26, Yiou Big Health learned thatBostonThe fourth-generation Vercise Genus deep brain stimulation (DBS) system developed by Boston Scientific Corporation has receivedFDAApproved for use in whole-body MRI scans, primarily indicated forParkinson's Diseaseas adjunctive therapy, will be launched soon.

During the treatment process with this system, patients must undergo surgery to implant an electrical pulse generator in brain regions responsible for controlling movement, pain, or emotion, which delivers electrical currents to stimulate neural pathways. It is understood that DBS therapy can alleviate neurological symptoms such as tremors, rigidity, and bradykinesia in patients with advanced Parkinson’s disease. This FDA approval allows the Vercise Genus DBS system to stimulate the subthalamic nucleus and globus pallidus internus to aid in the treatment of Parkinson’s disease.

Vercise Genus DBS has been in use in the United States and Europe for many years. Compared with previous generations of systems, the newly approved fourth-generation Vercise Genus DBS offers improved visualization capabilities, enabling physicians to deliver electrical signals more precisely to the target areas of the patient’s brain, thereby enhancing therapeutic efficacy.

For this product,Boston ScientificDr. Maulik Nanavaty, President of the Neuromodulation division, stated in a press release: “We will prioritize innovative therapies that enhance patients’ quality of life through personalized care. For individuals with movement disorders, Vercise Genus DPS signifies an improvement in daily living.”

Boston Scientific is a multinational giant in the field of minimally invasive medical devices, with a portfolio of over 13,000 innovative medical products. In 2019, Boston Scientific’s total sales amounted to approximately USD 10.7 billion. Boston Scientific entered the Chinese market in 1997 and has since established branches and R&D centers in cities such as Beijing and Guangzhou, with its China headquarters located in Shanghai.

In recent years, Boston Scientific has made building an ecosystem for medical innovation its primary strategy in China. In 2018, it jointly established the “T3 Innovation Hub” with the Technology Transfer Institute of Tsinghua University to incubate medical innovation projects. In 2019, Boston Scientific partnered with local organizations to found the China Cardiovascular Physicians Innovation Club (CCI) and signed an investment cooperation agreement with the Chengdu High-Tech Industrial Development Zone for the establishment of Boston Scientific’s “Second Headquarters” in China and an innovation center project, further strengthening its commitment to the western region and the broader Chinese market.

This article is sourced from Yiou, an original piece by author Mi Congcong. For reprints or collaborations, please click here.Reprint Notice, Unauthorized reproduction will be subject to legal action.